Results 181 to 190 of about 115,048 (305)

Interferon-alpha 2b early phase chronic Lymphocytic Leukemia with high risk for progression-first results of a randomized multicenter AIO-Study [PDF]

open access: yes, 1992
Dietzfelbinger, H.   +7 more
core   +1 more source

The association of thrombocytopenia with haematological malignancy

open access: yesBritish Journal of Haematology, EarlyView.
This review article discusses the interplay of immune dysregulation, clonality, and immunosuppressive therapies in immune thrombocytopenia and how this links to the risk of misattribution versus the development of haematological malignancy. Unresolved questions and directions for future research are also discussed. Isolated thrombocytopenia is commonly
Abi Vijenthira   +2 more
wiley   +1 more source

Incidence of severe COVID‐19 in patients with chronic lymphocytic leukaemia or indolent B‐cell non‐Hodgkin lymphoma who received vaccination and pre‐exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi

open access: yes
British Journal of Haematology, EarlyView.
Gian Matteo Rigolin   +25 more
wiley   +1 more source

Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival

open access: yesBrain Pathology, EarlyView.
Untargeted multiomic profiling of cerebrospinal fluid reveals that proteomic, but not lipidomic, signatures robustly distinguish ALS patients from controls and stratify individuals by survival, highlighting marked molecular differences between short survival and long survival disease.
Sergio Roca‐Pereira   +19 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy